Ropes & Gray Honored as a Law360 “Life Sciences Practice Group of the Year”

Law360 honored Ropes & Gray’s life sciences practice as a 2025 “Life Sciences Practice Group of the Year,” which recognizes the top attorney teams behind transformative deals and litigation that shaped the legal industry in the past year.

Our 200-lawyer cross-border life sciences team is embedded with clients from discovery to launch, combining transactional strength with regulatory fluency and litigation readiness. The firm is widely recognized for structuring innovative option-to-license arrangements, spin-outs and platform financings that accelerate innovation without sacrificing control and quality.

Ropes & Gray has built out its life sciences practice in a unique way — choosing to represent both Big Pharma and smaller biotechs, rather than choosing one side — the firm has emerged as an attractive adviser for hybrid M&A and licensing component deal structures.

From Oct. 2024 to Oct. 2025, the firm guided life sciences licensing transactions worth $118 billion across therapeutic areas, reflecting a market recalibrating around precision biology and capital efficiency. 

Ropes & Gray advised Sarepta Therapeutics through a transformational global licensing and collaboration agreement with Arrowhead Pharmaceuticals for multiple small interfering RNA (siRNA) programs, designed to inhibit specific genes in a deal worth up to $11.35 billion, one of the largest biopharmaceutical licensing deals by value, according to GlobalData.

The Law360 recognition underscores Ropes & Gray’s continued leadership in delivering sophisticated, cross-disciplinary counsel to life sciences innovators at every stage of growth.